XY-0206

N/A

Report date: 2025/05/13 16:53:06
NME

Base Information

Drug NameXY-0206
Drug Alias NameXY-0206
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsVascular endothelial growth factor receptor 2 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing University Of Chinese Medicine
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShijiazhuang Yiling Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A